LGK974
Based on 47 publication(s) in Google Scholar
LGK974 (WNT974) is an orally bioavailable and specific Porcupine (PORCN) inhibitor with an IC50 of 0.1 nM.
For research use only. We do not sell to patients.
- Purity: 99.93%
- CAS No.: 1243244-14-5
- Formula: C23H20N6O
- Molecular Weight:396.44
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Stem Cell Signaling Compound Library
HY-L017
-
Wnt/Hedgehog/Notch Compound Library
HY-L020
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
Anti-Aging Compound Library Mini
HY-L034M
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
Clinical Compound Library Plus
HY-L026P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) LGK974
More- Nature. 2017 May 18;545(7654):355-359. [Abstract]
- Cancer Cell. 2023 Sep 11;41(9):1621-1636.e8. [Abstract]
- Cell. 2026 Jun 4;189(13):3903-3921.e26.
- Cell Stem Cell. 2022 Aug 4;29(8):1246-1261.e6. [Abstract]
- Cell Stem Cell. 2020 Sep 3;27(3):413-429.e4. [Abstract]
- Bioact Mater. 2022 Jan 2:15:131-144. [Abstract]
- Sci Immunol. 2021 Nov 12;6(65):eabc6424. [Abstract]
- Nat Commun. 2019 Mar 27;10(1):1382. [Abstract]
- Adv Sci (Weinh). 2024 Mar;11(10):e2308072. [Abstract]
- Nat Chem Biol. 2025 May 26. [Abstract]
- J Clin Invest. 2026 Mar 17:e200260. [Abstract]
- Neuro Oncol. 2023 Jun 2;25(6):1073-1084. [Abstract]
- Exp Mol Med. 2021 Mar;53(3):407-421. [Abstract]
- Cancer Lett. 2023 Feb 1:554:216023. [Abstract]
- Oncogene. 2019 Mar;38(11):1951-1965. [Abstract]
- Cell Chem Biol. 2025 Oct 22:S2451-9456(25)00306-X. [Abstract]
- Cell Rep. 2023 May 23;42(6):112546. [Abstract]
- Neurotherapeutics. 2021 Jan;18(1):601-614. [Abstract]
- Br J Cancer. 2026 Jun;134(11):1671-1682. [Abstract]
- Clin Transl Med. 2024 May;14(5):e1670. [Abstract]
- Cancer Cell Int. 2023 Mar 16;23(1):46. [Abstract]
- Commun Biol. 2026 Feb 9;9(1):194. [Abstract]
- Drug Des Devel Ther. 2020 Aug 12;14:3301-3313. [Abstract]
- Int J Mol Sci. 2023 Dec 22;25(1):217. [Abstract]
- Int J Mol Sci. 2023 Apr 4;24(7):6733. [Abstract]
- Cell Mol Neurobiol. 2026 Jan 24;46(1):36.
- J Mol Struct. 2026 Feb 13.
- Int Immunopharmacol. 2024 Jan 25:127:111458. [Abstract]
- Mol Neurobiol. 2024 Apr;61(4):1936-1952. [Abstract]
- Sci Rep. 2025 Jan 7;15(1):1177. [Abstract]
- J Biol Chem. 2023 May;299(5):104645. [Abstract]
- J Biol Chem. 2018 Dec 21;293(51):19710-19724. [Abstract]
- Exp Cell Res. 2016 Jul 15;345(2):206-17. [Abstract]
- Anim Reprod Sci. 2025 Dec 4:285:108070. [Abstract]
- Dis Model Mech. 2025 Sep 11:dmm.052280. [Abstract]
- Mol Pain. 2025 Sep 5:17448069251380034. [Abstract]
- bioRxiv. 2026 May 19:2026.05.16.724973. [Abstract]
- SSRN. 2025 Sep 30.
- bioRxiv. 2025 Sep 10.
- bioRxiv. 2025 May 3:2025.04.29.651251. [Abstract]
- bioRxiv. 2025 Mar 29:2025.03.26.645490. [Abstract]
- Res Sq. 2025 Feb 11:rs.3.rs-4138879. [Abstract]
- bioRxiv. 2024 October 04.
- Pharmacological Research - Modern Chinese Medicine. 2024 Sep.
- Heidelberg University. 2024.
- bioRxiv. May 20, 2022.
- Research Square Preprint. 2021 Aug.
Customer Validation & Images
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
IF
Biological Activity
Porcupine[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Caco-2 | CC50 |
7.61 μM
Compound: LGK-974
|
Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
|
10.21203/rs.3.rs-23951/v1 |
| Caco-2 | IC50 |
3.27 μM
Compound: LGK-974
|
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
|
10.21203/rs.3.rs-23951/v1 |
| HCT-116 | IC50 |
>100 μM
Compound: LGK974
|
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Antiproliferative activity against human HCT-116 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
| HEK293 | IC50 |
0.9 nM
Compound: LGK974
|
Inhibition of Wnt signaling (unknown origin) expressed in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay
Inhibition of Wnt signaling (unknown origin) expressed in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay
|
[PMID: 26647303] |
| HEK293 | IC50 |
0.9 nM
Compound: LGK974
|
Inhibition of porcupine in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay
Inhibition of porcupine in mouse L Wnt3A cells co-cultured with HEK293 cells after 48 hrs by Super-top flash reporter gene assay
|
[PMID: 27692509] |
| HT-1080 | IC50 |
0.4 nM
Compound: LGK974
|
Inhibition of porcupine activity (unknown origin) expressed in human HT1080 cells assessed as suppression of Wnt3A-mediated super top flash activity by STF luciferase assay
Inhibition of porcupine activity (unknown origin) expressed in human HT1080 cells assessed as suppression of Wnt3A-mediated super top flash activity by STF luciferase assay
|
[PMID: 26522946] |
| MCF-10A | IC50 |
>100 μM
Compound: LGK974
|
Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Cytotoxicity against human MCF-10A cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: LGK974
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
| MDA-MB-468 | IC50 |
>100 μM
Compound: LGK974
|
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
| SW480 | IC50 |
>100 μM
Compound: LGK974
|
Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
Antiproliferative activity against human SW480 cells assessed as cell growth inhibition measured after 72 hrs by MTS assay
|
[PMID: 34382808] |
LGK974 effectively displaces [3H]-GNF-1331 with an IC50 of 1 nM in the PORCN radioligand binding assay. LGK974 potently reduces Wnt-dependent AXIN2 mRNA levels in HN30 cells with an IC50 of 0.3 nM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1243244-14-5
-
Appearance Solid
-
Molecular Weight 396.44
-
Formula C23H20N6O
-
Color White to light brown
-
SMILES
O=C(NC1=NC=C(C2=NC=CN=C2)C=C1)CC3=CN=C(C4=CC(C)=NC=C4)C(C)=C3
-
Synonyms
WNT974
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (47)
-
Journal Impact Factor
-
Most Recent
-
Nature
A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. [Abstract]2017 May 18;545(7654):355-359. PMID: 28489818 -
Cancer Cell
CD44+ lung cancer stem cell-derived pericyte-like cells cause brain metastases through GPR124-enhanced trans-endothelial migration. [Abstract]2023 Sep 11;41(9):1621-1636.e8. PMID: 37595587 -
-
Cell Stem Cell
2022 Aug 4;29(8):1246-1261.e6. PMID: 35931033 -
Cell Stem Cell
Distinct Spatiotemporally Dynamic Wnt-Secreting Niches Regulate Proximal Airway Regeneration and Aging. [Abstract]2020 Sep 3;27(3):413-429.e4. PMID: 32721381
LGK974 purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2020 Sep 3;27(3):413-429.e4. [Abstract]
IF images of uninjured, 48 hpi, and 72 hpi mouse airway epithelia wild-type mice treated with vehicle or LGK974 assessing BrdU incorporation. Relative to vehicle-treated mice, LGK974-treated mice exhibited an attenuated SAE with few BrdU+ ABSCs, thereby phenocopying the repair response of K5-CreER;Ctnnb1fl/fl mouse tracheas.
-
Bioact Mater
2022 Jan 2:15:131-144. PMID: 35386336 -
Sci Immunol
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. [Abstract]2021 Nov 12;6(65):eabc6424. PMID: 34767457 -
Nat Commun
FBXW2 suppresses migration and invasion of lung cancer cells via promoting β-catenin ubiquitylation and degradation. [Abstract]2019 Mar 27;10(1):1382. PMID: 30918250 -
Adv Sci (Weinh)
2024 Mar;11(10):e2308072. PMID: 38239021 -
Nat Chem Biol
2025 May 26. PMID: 40419770 -
J Clin Invest
Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity. [Abstract]2026 Mar 17:e200260. PMID: 41842971 -
Neuro Oncol
Wnt Signaling Regulates MFSD2A-dependent Drug Delivery through Endothelial Transcytosis in Glioma. [Abstract]2023 Jun 2;25(6):1073-1084. PMID: 36591963
LGK974 purchased from MedChemExpress. Usage Cited in: Neuro Oncol. 2023 Jun 2;25(6):1073-1084. [Abstract]
LGK974 (2.5 mg/kg; 4 days; i.g.). Immunohistochemical staining of CD31 in RCAS/tv-a glioma from mice treated with or without LGK974 was performed.
LGK974 purchased from MedChemExpress. Usage Cited in: Neuro Oncol. 2023 Jun 2;25(6):1073-1084. [Abstract]
LGK974 (2.5 mg/kg; 4 days; i.g.). Co-immunofluorescence staining and quantification of β-catenin and CD31 in RCAS/tv-a glioma tumors from mice treated with or without LGK974 were performed.
LGK974 purchased from MedChemExpress. Usage Cited in: Neuro Oncol. 2023 Jun 2;25(6):1073-1084. [Abstract]
LGK974 (2.5 mg/kg; 4 days; i.g.) was administered. The survival curve of CT-2A glioma-bearing mice treated with LGK974 and/or TMZ was analyzed.
-
Exp Mol Med
LGK974 suppresses lipopolysaccharide-induced endotoxemia in mice by modulating the crosstalk between the Wnt/β-catenin and NF-κB pathways. [Abstract]2021 Mar;53(3):407-421. PMID: 33692475
LGK974 purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2021 Mar;53(3):407-421. [Abstract]
C57BL/6 mice were injected i.p. with 0–60 mg/kg LGK974 2 h before being injected with 25 mg/kg LPS. Cytokine concentrations in the plasma were determined using a magnetic Luminex assay.
-
Cancer Lett
CircPTK2/PABPC1/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer. [Abstract]2023 Feb 1:554:216023. PMID: 36436682 -
Oncogene
Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance. [Abstract]2019 Mar;38(11):1951-1965. PMID: 30390075 -
Cell Chem Biol
STT3A is essential for Wnt signaling and represents a target for cancers driven by RNF43 deficiency. [Abstract]2025 Oct 22:S2451-9456(25)00306-X. PMID: 41130209 -
Cell Rep
2023 May 23;42(6):112546. PMID: 37224015 -
Neurotherapeutics
Blockers of Wnt3a, Wnt10a, or β-Catenin Prevent Chemotherapy-Induced Neuropathic Pain In Vivo. [Abstract]2021 Jan;18(1):601-614. PMID: 33128175 -
Br J Cancer
Nuclear FGF2, androgen receptor and Wnt pathway activation define a targetable subset of antiprogestin-resistant luminal breast cancer. [Abstract]2026 Jun;134(11):1671-1682. PMID: 41935240 -
Clin Transl Med
2024 May;14(5):e1670. PMID: 38689429 -
Cancer Cell Int
BRF2 is mediated by microRNA-409-3p and promotes invasion and metastasis of HCC through the Wnt/β-catenin pathway. [Abstract]2023 Mar 16;23(1):46. PMID: 36927769 -
Commun Biol
Wnt11 mediates fibroblast-smooth muscle cell interaction to promote neurogenic bladder fibrosis in rats. [Abstract]2026 Feb 9;9(1):194. PMID: 41663583 -
Drug Des Devel Ther
2020 Aug 12;14:3301-3313. PMID: 32848368 -
Int J Mol Sci
2023 Dec 22;25(1):217. PMID: 38203386 -
Int J Mol Sci
2023 Apr 4;24(7):6733. PMID: 37047705 -
-
-
Int Immunopharmacol
2024 Jan 25:127:111458. PMID: 38160565 -
Mol Neurobiol
Teriflunomide Promotes Blood-Brain Barrier Integrity by Upregulating Claudin-1 via the Wnt/β-catenin Signaling Pathway in Multiple Sclerosis. [Abstract]2024 Apr;61(4):1936-1952. PMID: 37819429 -
Sci Rep
The effects of the Wnt/β-catenin signaling pathway on the in vitro differentiation of rat BMSCs into leydig cells. [Abstract]2025 Jan 7;15(1):1177. PMID: 39775149 -
J Biol Chem
The Wnt pathway protein Dvl1 targets Somatostatin receptor 2 for lysosome-dependent degradation. [Abstract]2023 May;299(5):104645. PMID: 36965619 -
J Biol Chem
Oligomerization of Frizzled and LRP5/6 protein initiates intracellular signaling for the canonical WNT/β-catenin pathway. [Abstract]2018 Dec 21;293(51):19710-19724. PMID: 30361437 -
Exp Cell Res
WNT/β-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. [Abstract]2016 Jul 15;345(2):206-17. PMID: 27321958
LGK974 purchased from MedChemExpress. Usage Cited in: Exp Cell Res. 2016 Jul 15;345(2):206-17. [Abstract]
Inhibition of PORCN abolishes Runx2 induction stimulated by β-GP. VSMCs are pretreated with LGK974 (1nM) for 30 min, then incubated with β-GP (10mM) for 24h, and the cell lysates are immunoblotted with antibodies against Runx2 and β-actin, respectively.
-
Anim Reprod Sci
Pharmacological activation of Wnt/β-catenin signaling is essential for oocyte developmental competence and enhances in vitro embryo production in water buffalo. [Abstract]2025 Dec 4:285:108070. PMID: 41365046 -
Dis Model Mech
The class A repeats of Lrp5 are required for normal development of bone, retinal vasculature, and mammary gland in vivo. [Abstract]2025 Sep 11:dmm.052280. PMID: 40932232 -
Mol Pain
EXPRESS: Exacerbation of paclitaxel-induced neuropathic pain behaviors in breast tumor-bearing mice. [Abstract]2025 Sep 5:17448069251380034. PMID: 40913249 -
bioRxiv
Elongin B orchestrates chromatin and transcriptional programs in H3K27M-mutant diffuse midline glioma. [Abstract]2026 May 19:2026.05.16.724973. PMID: 42239282 -
-
-
bioRxiv
NF2 loss malignantly transforms human pancreatic acinar cells and enhances cell fitness under environmental stress. [Abstract]2025 May 3:2025.04.29.651251. PMID: 40655016 -
bioRxiv
Dyr726, a brain-penetrant inhibitor of PI3Kα, Type III receptor tyrosine kinases, and WNT signaling. [Abstract]2025 Mar 29:2025.03.26.645490. PMID: 40196701 -
Res Sq
2025 Feb 11:rs.3.rs-4138879. PMID: 39989975 -
-
-
-
-
Solvent & Solubility
DMSO : 125 mg/mL (315.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 8.33 mg/mL (21.01 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (6.31 mM); Suspended solution; Need ultrasonic and warming
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
HN30 cells and UMSCC cells are used. For TaqMan assay, 2×106 cells per well are plated into six-well cell culture plates and treated with or without LGK974 in amultipoint dose-response. RNA samples are collected after 48 h. For colony formation assays, 2×103 cells per well are plated into six-well cell culture plates with or without compound treatment. Cells are stained with crystal violet 1 wk later[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice and Rats[1]
Nude mice (or nude rats) bearing the mouse mammary tumor virus-Wnt1, HN30, or SNU1076 tumors are randomized according to tumor volume. LGK974 is formulated in 10% (vol/vol) citrate buffer (pH 2.8)/90% (vol/vol) citrate buffer (pH 3.0) or 0.5% MC/0.5% Tween 80 and administered by oral gavage at a dosing volume of 10 μL/g animal body weight. Body weight is monitored daily, and tumor sizes are assessed three times per week after the tumors are palpable. Tumor sizes are determined by using caliper measurements. Tumor volumes are calculated with a formula (length×width×height)/2. The plasma concentrations and exposures of LGK974 in the tumor-bearing nude mice (n=2 per dosing group) are determined on day 14. Blood samples (50 μL) are collected by serial retroorbital sampling at 1, 3, 7, 16, and 24 h postdose. The blood samples are centrifuged, and plasma is separated and frozen until analysis by liquid chromatography/MS/MS. For tolerability studies, LGK974 is administrated to nontumor-bearing Wistar rats one time per day by oral gavage at 3 or 20 mg/kg per day. Necropsies are performed at the end of the study. Tissues are fixed in 10% (vol/vol) neutralbuffered formalin, sectioned, and subjected to H&E staining.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Liu J, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20224-9. [Content Brief]
[2]. Tammela T, et al. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature. 2017 May 18;545(7654):355-359. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 2.5224 mL | 12.6122 mL | 25.2245 mL | 63.0612 mL |
| 5 mM | 0.5045 mL | 2.5224 mL | 5.0449 mL | 12.6122 mL | |
| 10 mM | 0.2522 mL | 1.2612 mL | 2.5224 mL | 6.3061 mL | |
| 15 mM | 0.1682 mL | 0.8408 mL | 1.6816 mL | 4.2041 mL | |
| 20 mM | 0.1261 mL | 0.6306 mL | 1.2612 mL | 3.1531 mL | |
| DMSO | 25 mM | 0.1009 mL | 0.5045 mL | 1.0090 mL | 2.5224 mL |
| 30 mM | 0.0841 mL | 0.4204 mL | 0.8408 mL | 2.1020 mL | |
| 40 mM | 0.0631 mL | 0.3153 mL | 0.6306 mL | 1.5765 mL | |
| 50 mM | 0.0504 mL | 0.2522 mL | 0.5045 mL | 1.2612 mL | |
| 60 mM | 0.0420 mL | 0.2102 mL | 0.4204 mL | 1.0510 mL | |
| 80 mM | 0.0315 mL | 0.1577 mL | 0.3153 mL | 0.7883 mL | |
| 100 mM | 0.0252 mL | 0.1261 mL | 0.2522 mL | 0.6306 mL |
Powered by Bioz